Nexthera Capital LP lowered its stake in Zosano Pharma Corporation (NASDAQ:ZSAN) by 16.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 418,350 shares of the biotechnology company’s stock after selling 81,650 shares during the period. Nexthera Capital LP owned approximately 1.07% of Zosano Pharma Corporation worth $590,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZSAN. Endurant Capital Management LP purchased a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $1,135,000. Perceptive Advisors LLC purchased a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Victory Capital Management Inc. purchased a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $449,000. Vanguard Group Inc. boosted its position in shares of Zosano Pharma Corporation by 20.8% during the second quarter. Vanguard Group Inc. now owns 1,217,323 shares of the biotechnology company’s stock valued at $1,716,000 after buying an additional 209,251 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Zosano Pharma Corporation by 591.4% during the second quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 67,774 shares during the period. Institutional investors own 22.66% of the company’s stock.

Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) traded up 0.9990% on Thursday, hitting $0.8391. The company’s stock had a trading volume of 66,796 shares. The firm’s market cap is $32.92 million. The stock has a 50-day moving average price of $0.90 and a 200 day moving average price of $0.90. Zosano Pharma Corporation has a one year low of $0.45 and a one year high of $3.54.

Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). During the same quarter last year, the firm earned ($0.54) EPS. Equities research analysts predict that Zosano Pharma Corporation will post ($0.85) EPS for the current year.

Separately, ValuEngine upgraded Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

TRADEMARK VIOLATION NOTICE: “Nexthera Capital LP Sells 81,650 Shares of Zosano Pharma Corporation (ZSAN)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/nexthera-capital-lp-sells-81650-shares-of-zosano-pharma-corporation-zsan/1610192.html.

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Want to see what other hedge funds are holding ZSAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zosano Pharma Corporation (NASDAQ:ZSAN).

Institutional Ownership by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.